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Traditional antibiotic dosing was not designed for today’s escalating antibiotic resistance, lack of novel antibiotics
and growing complexity in patient populations. Dosing that ensures optimal antibiotic exposures should be con-
sidered essential to increase the likelihood of effective patient treatment. Given the variability in these exposures
across different patients, a ‘one-dose-fits-all’ approach is increasingly problematic. Therapeutic drug monitoring
(TDM) of the b-lactams, the most widely used antibiotic class, is underutilized in certain populations. Clinical
experience with b-lactam TDM remains relatively scarce. Patients most likely to benefit from such an intervention
include the critically ill, the obese, the elderly and those with cystic fibrosis. Most centres actively performing
b-lactam TDM target a minimum 100% of the time during the dosing interval that the free (unbound) concen-
tration of antibiotic exceeds the MIC of the pathogen (100% fT.MIC), which is higher than a traditional target
supported by in vitro data. Ideally, isolated pathogens should undergo MIC testing along with TDM on a regular
basis, allowing clinicians to address the triad of bug, drug and patient (‘mug’) in equal measure.
Introduction: bug, drug and ‘mug’
Antibiotic resistance is increasing more rapidly than previously
forecast.1 In earlier decades the average lag time for resistance
development after an antibiotic’s registration was roughly
10 years, but there is now evidence of widespread resistance to
novel drugs in countries where these compounds have not yet
been introduced.2 At the same time, the pipeline for antibiotics
with novel mechanisms of action is nearly dry.3 This backdrop
mandates the urgent optimization of the way we manage our
existing antibiotics.
Meanwhile, the patient populations treated in the healthcare
system are rapidly changing. The proportion of geriatric patients
is growing steadily, while worldwide obesity rates have nearly
doubled since 1980.4 Patients with cystic fibrosis are living longer
and being exposed to more antibiotic courses.5 At the outset of
the antibiotic era, patients could rarely be maintained in pro-
longed states of severe illness. Now they may remain critically
ill for weeks or months; in that time rapid dynamic changes in
physiology,6 including phenomena such as augmented renal
clearance7 and also renal and hepatic dysfunction, can lead to
unpredictable pharmacokinetic alterations that affect antibiotic
exposure.8 Broader use of supportive extracorporeal therapies
such as continuous renal replacement therapy and extracorporeal
membrane oxygenation further complicate the pharmacokinetic
behaviour of antibiotics.9 Meanwhile the critically ill, with their
ventilatory and feeding tubes, catheters and drains, must share
limited space and medical staff, creating an ideal setting for the
emergence and spread of resistance. This population, whose
pooled annual antibiotic consumption can be measured in
tons,10 is increasingly colonized or infected with bacteria whose
susceptibilities have decreased since these antibiotics were first
clinically tested.
The old landscape was one of lower MICs and relatively homo-
geneous patient types; here the simple dichotomy of ‘bug versus
drug’, informed largely by in vitro studies, sufficed. Fixed dosing
regimens appeared to suffice as well. The new landscape, how-
ever, is marked by less-susceptible microorganisms, patients
often suspended in previously unknown extremes of pathophysi-
ology and an absence of novel ‘magic bullets’. This requires
adjustment to a trichotomy in which the host, or ‘mug’, plays a
role equal to those of bug and drug.11 Indeed, a shift towards indi-
vidualized antibiotic therapy to maximize the effectiveness of our
available antibiotics is inevitable12 given limited alternative
options.
Yet our ignorance of the host’s role in antibiotic exposure and
efficacy, especially those of the b-lactams, the cornerstone of
anti-infective therapy, is not negligible. Most of the pharmacoki-
netic data informing both clinical trials and routine practice are
provided by young, healthy volunteers whose physiology differs
markedly from that of sick patients. In most hospitals worldwide
today, patients are given a standard, fixed-dose regimen and
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clinicians have little means of confirming achievement of thera-
peutic exposures beyond the presence or absence of clinical
response days or weeks later.
Historically, therapeutic drug monitoring (TDM) for the
b-lactams was not introduced into routine practice because
these antibiotics do not have a narrow therapeutic window.
Now, however, given increasing acquired resistance to b-lactams
and its association with low antibiotic serum concentrations,13
b-lactam TDM in certain populations may bear more clinical
relevance.
In this paper, we review the data relating to the rationale for
b-lactam TDM, identify the populations likely to benefit from its
use and describe both the pharmacokinetic/pharmacodynamic
targets favoured by current proponents and the challenges that
institutions may face in its implementation.
b-Lactam antibiotics and current dosing
schemes
The most widely used group of antibiotics, the b-lactams have long
been at the front line of patient care. Penicillin derivatives, cepha-
losporins, monobactams and carbapenems all contain a core
b-lactam ring and target bacterial penicillin-binding proteins, inhi-
biting cell-wall synthesis and causing cell lysis. Pharmacokinetic/
pharmacodynamic studies have consistently shown that max-
imum killing occurs at concentrations 3–4 times the MIC, with
higher concentrations offering little additional bacterial killing.14
Despite this, the effectiveness of b-lactam antibiotics ultimately
depends more on the duration of exposure than on the magnitude
of their concentration.14 The longer a b-lactam antibiotic is present
at the site of infection at a free (unbound) concentration superior to
the targeted pathogen’s MIC (fT.MIC), the more effectively bacteri-
cidal it is. In this context, b-lactams exhibit time-dependent
activity.15–17
Current dosing schemes are primarily derived from a mixture of
pre-clinical infection models and Phase 1 pharmacokinetic data.
But an identical dose of a b-lactam may lead to markedly differ-
ent antibiotic exposures in healthy volunteers versus patients,
including critically ill, obese or elderly patients. Critically ill patients
in particular are known to undergo rapid changes in physiology
that fundamentally alter their pharmacokinetics.12 Patients with
sepsis become hyperdynamic, with increased renal blood flow
and glomerular filtration that can result in augmented renal clear-
ance of many drugs, among them the b-lactams.18 These phar-
macokinetic changes also occur with post-trauma, post-major
surgery, burns and transplant patients.6,19,20 Critically ill patients
may also develop capillary leak syndrome, resulting in increased
interstitial fluid volumes; these in turn lead to an increased vol-
ume of distribution of most b-lactams.21 Conversely, patients
may develop end-organ dysfunction and thus impaired drug dis-
tribution and clearance.22 The presence of renal replacement
therapy in particular introduces further challenges to optimal dos-
ing. The combination of these different pathophysiological effects
leads to highly variable and significant changes in pharmacokin-
etics not only between patients, but also within the same patient.
In this setting, use of loading doses to account for the increased
volumes of distribution should be considered, as should altered
maintenance doses that are appropriate for the possible pro-
longation of drug half-life.
Figure 1 demonstrates the contrast in mean imipenem serum
concentrations throughout the dosing interval in healthy volun-
teers23 and in 54 adult patients in an ICU with at least moderate
renal function at the start of therapy.24 The critically ill patients
clearly have consistently lower concentrations than healthy
volunteers receiving the same dose, with mean concentrations
below the MICs of several ICU pathogens. Similarly discordant
pharmacokinetics have been demonstrated for b-lactams in
patients with febrile neutropenia.25
The pharmacokinetics of antibiotics in the obese remain largely
unknown, though it is evident that they diverge significantly from
those in the non-obese.26,27 Obese patients may have reduced
total exposure of orally administered antibiotics, while most anti-
biotic classes demonstrate an increased volume of distribution in
this population. Though obesity is associated with an increase
in renal clearance, this is often countered by a higher incidence
of renal dysfunction over time. For instance, the presence of
comorbidities such as diabetes mellitus is associated with an ele-
vated renal clearance in the first years of the disease, which later
leads to chronic kidney disease and impaired drug clearance. This
bidirectional effect and the fact that commonly used creatinine
clearance calculations may be inaccurate in the obese together
result in antibiotic exposure that is difficult to predict.26
Antibiotic pharmacokinetics in geriatric patients differ as well.
Elderly patients have impaired homeostasis and wider inter-
individual variability. While it is known that ageing is associated
with reduced drug absorption from the gastrointestinal tract, pro-
tein binding and overall drug distribution,28 there are few clinical
trials specifically comparing clinical outcomes as a function of
drug dosage in this and younger populations. In these geriatric
patients accurate descriptions of organ function in particular are
required to ensure effective dosing, particularly as reducing renal
clearance of drugs is likely in these patients.
Patients with cystic fibrosis are also a challenging patient group
where pharmacokinetic changes for renally cleared drugs such as
b-lactam antibiotics are common.29 These patients tend to dis-
play increased b-lactam clearances, whilst volume of distribution
remains largely unchanged.30
When clinical testing of antibiotics in infected patients does
occur, it is usually for pre-specified, mild or moderate infections in
limited populations with little comorbidity or obesity. Meropenem
was not tested widely in patients with pneumonia and, although
approved for this indication in some countries, it is not widely




















Figure 1. Mean (SD) serum imipenem concentrations in eight healthy
volunteers (black)23 and in 54 critically ill patients (grey) throughout the




approved for pneumonia even though this appears to be its most
frequent use in critically ill patients worldwide. The anti-MRSA ceph-
alosporin ceftobiprole has been studied and approved only for skin
and skin structure infections (SSSIs),31 yet it is frequently used off-
label in some countries for ventilator-associated pneumonia (VAP)
at these recommended doses despite indications that these are
unlikely to achieve pharmacodynamic targets in patients with VAP.32
In addition, the majority of currently used b-lactams underwent
clinical outcome testing in Phase 3 trials several decades ago,
when MICs for many organisms were lower. Longitudinal surveil-
lance programmes document steady decreases in the suscepti-
bility of several Gram-negative (Escherichia coli, Klebsiella spp.,
Pseudomonas aeruginosa etc.) and Gram-positive (Staphylococcus
aureus, Streptococcus spp., Enterococcus spp. etc.) bacteria to
b-lactam and other antibiotics since then.33,34
It is thus highly unlikely that optimal antibiotic exposure will be
achieved with traditional doses in certain patient groups. Various
options for dose optimization of b-lactam antibiotics have been
explored. Dosing nomograms have proven largely unable to pro-
vide acceptable achievement of target exposures.12,35,36 Dosing
based primarily on calculated creatinine clearance has also pro-
ven suboptimal,37 and even well-designed continuous or
extended infusions of b-lactams may fail to consistently achieve
target exposures.19,38,39 Thus TDM would appear useful, not only
to avoid underdosing in patients with elevated drug clearances,
but also to minimize the likelihood of drug toxicity (e.g. encephal-
opathy and seizures) in patients with impaired drug clearance.40
TDM of the b-lactam antibiotics: current state
The great advantage of b-lactam TDM is that it provides actual
measurements of serum antibiotic exposures so that dosing can
be adapted to ensure optimal exposures are achieved. Ideally,
these should be interpreted in concert with the antibiotic’s MIC
for the causative pathogen to guide therapy, and with the nature
and site of infection.
We estimate that at this time 30 hospitals worldwide are
now performing b-lactam TDM on a routine basis, the majority
for critically ill patients, with a great deal of heterogeneity in
their approaches. A recent survey on the conduct of b-lactam
TDM in ICU settings revealed diversity in the type of b-lactams
measured, the patients selected for TDM and drug assay meth-
ods.41 Only two of the nine centres surveyed measure the
unbound, and therefore active, concentrations of b-lactams
(unbound measurement is likely to be more costly than total con-
centrations); the rest measure total concentrations with correc-
tions for protein-bound drug based on published data from
non-critically ill patients. While most b-lactam antibiotics have
only low protein binding (exceptions include flucloxacillin, oxacillin,
ceftriaxone, cefazolin and ertapenem),42,43 certain patient popula-
tions demonstrate significant hypoalbuminaemia. Measurement of
total antibiotic concentrations in the presence of hypoalbuminae-
mia can lead to misinterpretation and potentially inappropriate
dosing regimen adjustments or non-adjustments.44
Pharmacokinetic targets used by sites currently applying
b-lactam TDM appear equally variable. The majority of centres
target b-lactam concentrations with 100% fT.MIC, but some
favour up to 100% fT.4×MIC, while a few target 50% fT.4×MIC or
70% fT.4×MIC for certain b-lactams.
41 Indeed, whether a
b-lactam’s serum concentration needs to be above the MIC at
all times (100% fT.MIC) requires prospective clinical validation.
Although intuitively 100% fT.MIC would seem to be a safe target
to ensure maximal antibiotic exposure, early in vitro pharmacoki-
netic/pharmacodynamic studies of some b-lactams suggest that
such prolonged exposures may not be necessary.16
Time dependence and pharmacokinetic/
pharmacodynamic targets
Murine infection models from the 1980s to the 2000s suggest
that certain antibiotics’ fT.MIC need only be 40%–60% for certain
organisms.16,17,45 Given that standard b-lactam dosing regimens
target an exposure of50% fT.MIC, it would seem that if a higher
exposure were absolutely necessary, then the current practice
should be associated with chronic underdosing and therapeutic
failure. Yet there is currently only modest evidence in humans
that b-lactam 100% fT.MIC concentrations translate to improved
clinical outcome, possibly because the issue has yet to be investi-
gated in a robust prospective manner, but also because of differ-
ences between studied patients in terms of how representative
blood concentrations are of infection site concentrations and dif-
ferences in the inoculum of different infections, as well as patient
immunocompetence. The recent DALI study, a multinational
point-prevalence analysis of intermediate (50% fT.MIC) and
trough (100% fT.MIC) b-lactam serum concentrations in 384
patients across 68 ICUs, found an association between positive
clinical outcome and an increasing 100% fT.MIC ratio (OR 1.53,
P,0.03). Though hampered by a lack of universal MIC measure-
ments, the study found that the 16% of patients who did not
achieve even 50% fT.MIC were 32% less likely to have a positive
clinical outcome.19 The association between increasing antibiotic
exposure above 50% fT.MIC and clinical cure may support a higher
target, such as 100% fT.MIC for critically ill patients. Other popula-
tions remain understudied in this regard.
Interestingly, even altered dosing approaches intended to
increase fT.MIC, such as continuous infusion of b-lactams, may
not always achieve pharmacokinetic/pharmacodynamic targets.
A recent trial randomized 60 patients with severe sepsis to
b-lactam therapy via either intermittent dosing or continuous
infusion; 82% and only 29% of those receiving continuous infu-
sion and intermittent dosing, respectively, achieved 100%
fT.MIC for targeted pathogens.
46 While clinical cure was higher
in the continuous infusion group (70% versus 43%; P¼0.037),
ICU-free days (19.5 versus 17; P¼0.14) and survival to hospital
discharge (90% versus 80%, P¼0.47) did not significantly differ
between groups.
Nonetheless, like optimal antibiotic therapy, pharmacokinetic/
pharmacodynamic targets must also be individualized. Sufficient tis-
sue exposure will require different serum concentrations depending
on where those tissues are and what antibiotic is being adminis-
tered. For example, while cefepime appears to penetrate lung epi-
thelial lining fluid (ELF) fully, ceftazidime has an ELF-to-serum
concentration ratio of only 0.2.47,48 Pharmacokinetics change in
relation to the patient’s infective state itself; it has long been
known that optimal CSF concentrations of most b-lactams are
more likely to be achieved in the presence of meningeal inflamma-
tion.49 Furthermore, targets for bactericidal effect are different from
those preventing the emergence of drug resistance, as the former
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often do not adequately suppress the growth of resistant sub-
populations, especially in rapidly adaptive pathogens such as
P. aeruginosa.50
But until validated sampling and software tools12 that would
allow the identification of individual pharmacokinetic targets
become widely available, serum trough concentrations of
at least 100% fT.MIC can, in our view, provide a reasonably reli-
able confirmation of appropriate exposure in most clinical
circumstances.
For practical reasons, where b-lactam trough concentrations
are to be taken, the blood samples could be drawn once pharma-
cokinetic steady state has been reached (24 h after the start of
therapy) to ensure attainment of this target.6 Alternatively and
preferably, where a Bayesian adaptive feedback approach is avail-
able, sampling could occur during the first dosing interval to allow
even more rapid prediction of optimized dosing.12 Open-source,
web-based programs are available for this approach, which still
requires clinical testing in randomized trials.12,51
b-Lactam TDM and MIC determination
According to the survey from Wong et al.,41 very few hospital cen-
tres today have instituted routine b-lactam TDM with concomitant
pathogen MIC determination. The majority of centres performing
TDM instead use local antibiograms or EUCAST breakpoints as sur-
rogates for the actual MIC. Using epidemiological MIC breakpoints
should ensure that all patients will achieve pharmacokinetic/
pharmacodynamic targets, but clearly many patients will also
have unnecessarily high doses when the infection is caused by
highly susceptible pathogens. However, such high doses should
be considered acceptable as these loading doses can also ensure
maximal efficacy in the presence of pharmacokinetic changes
and also the presence of a high inoculum of pathogens.
Indeed, timely MIC testing of the causative pathogen should
be a fundamental aspect of TDM—but, as for aminoglycosides
and glycopeptides, it is a frequently absent partner. EUCAST and
CLSI breakpoints are essentially indicators constructed to err on
the side of clinical caution, with high cut-offs for presumed sus-
ceptibility; as such they may not be applicable to local resistance
patterns. Direct MIC testing is both time consuming and labour
intensive. While newer automated methods such as Etestw and
Vitek2w are promising, the results are apparently not frequently
reported to clinicians.41 A more widespread use of b-lactam MIC
testing in conjunction with TDM would allow truly individualized
and optimized drug therapy.52
What are the issues preventing institutions
providing b-lactam TDM?
The first issue likely to be preventing wide-scale adoption of
b-lactam TDM programmes is the absence of a prospective rando-
mized controlled trial demonstrating either a clinical or an eco-
nomic benefit of such an intervention. To date, no such trial has
been attempted to our knowledge. In fact, a randomized trial
assessing a ‘hard clinical endpoint’ such as mortality may be
exceedingly difficult to undertake because the institutions that
have the b-lactam assay available may not have clinical equipoise
as to the efficacy of TDM and therefore would find it ethically chal-
lenging to randomize patients to a treatment that is not the
standard of care at their institution. It follows that clinical or
economic evidence quantifying the benefits of b-lactam TDM
may not be forthcoming in the immediate future.
The requirement for a chromatography-based method for
analysing b-lactam concentrations is the second and perhaps
larger issue preventing the introduction of routine b-lactam TDM
services. Not only is the relative turnaround time (6–24 h) longer
than those of other techniques (e.g. results of immunoassays for
aminoglycosides and glycopeptides may be available within
30 min), but equipment can be expensive and requires skilled
operators, providing a recurring equipment and staff cost for the
institution. Given the importance of achieving effective exposures
in the patient groups highlighted above, this chromatographic
assay should also be available 24 h a day 7 days a week, which
introduces additional infrastructure, staff and training costs. Of
interest, the cost of measuring one b-lactam serum concentra-
tion varies, but is roughly USD 30/assay (20 E) in a central labora-
tory. Whilst some cost savings may be realized from dose
decreases for infection with pathogens with lower MICs, unless
changes to service utilization in terms of reduced duration of ther-
apy or patient length of stay can be demonstrated, b-lactam TDM
may always appear to represent a cost burden.
Finally, a collaborative approach between the treating team,
infectious disease physicians, microbiologists, clinical pharmacists
and the laboratory needs to be established with adherence to an
agreed protocol for sampling and dose modification. This service
can be successful and long lasting, as evidenced by the existing
b-lactam TDM programmes in place at institutions around
the world.
Conclusions
At present, TDM of the b-lactam antibiotics is probably not war-
ranted with relatively mild infections and/or a low risk of less-
susceptible pathogens. In populations with grossly varied and
unpredictable pharmacokinetics however, or those with infections
due to pathogens with high MICs, b-lactam TDM would appear
highly relevant. We would conclude there is only indirect evidence
supporting b-lactam TDM as an intervention leading to improved
outcomes and a randomized controlled trial quantifying such a
benefit is yet to be conducted.
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